Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.

McCann N. et al, (2023), BMJ Open, 13

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).

Koen AL. et al, (2023), Vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Yin Z. et al, (2023), Cell Rep, 42

COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case-control study with SARS-CoV-2 genetic sequencing.

Bijukchhe SM. et al, (2023), BMJ Open, 13

Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.

Khanam F. et al, (2023), Vaccine

Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.

Dold C. et al, (2023), Vaccine

Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis

Khanam F. et al, (2023), eClinicalMedicine, 58

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.

Mao Z. et al, (2023), Vaccine

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.

Moore SC. et al, (2023), Med (N Y)

Correction to: Febrile illness in high-risk children: a prospective, international observational study.

van der Velden FJS. et al, (2023), Eur J Pediatr, 182, 555 - 556

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.

Green C. et al, (2023), Clin Exp Immunol

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials

EWER K., (2023), Clinical and Experimental Immunology

Polio eradication: Addressing the hurdles on the last mile

Thompson KM. et al, (2023), Cell, 186, 1 - 4

A tool for evaluating heterogeneity in avidity of polyclonal antibodies.

Li K. et al, (2023), Front Immunol, 14

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.

Wildenbeest JG. et al, (2022), Lancet Respir Med

Distinct glycosylation and functional profile of typhoid vaccine-induced antibodies in a UK challenge study and Nepalese children.

HILL J. et al, (2022), Frontiers in Analytical Science

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Madhi SA. et al, (2022), Lancet Infect Dis

Febrile illness in high-risk children: a prospective, international observational study.

van der Velden FJS. et al, (2022), Eur J Pediatr

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2022), Nat Med

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?